MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy PipelineGlobeNewsWire • 11/10/22
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/03/22
MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 10/20/22
MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 07/27/22
MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 04/27/22
MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/18/22
MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business UpdateGlobeNewsWire • 03/03/22
MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor CancersGlobeNewsWire • 03/03/22
MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology ConferenceGlobeNewsWire • 01/12/22
MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/17/21
MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797GlobeNewsWire • 11/12/21